Lipella Pharmaceuticals (LIPO) Stock Forecast, Price Target & Predictions
LIPO Stock Forecast
Lipella Pharmaceuticals stock forecast is as follows: an average price target of $2.00 (represents a -17.36% downside from LIPO’s last price of $2.42) and
LIPO Price Target
Lipella Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 09, 2024 | Jason McCarthy | Maxim Group | $2.00 | $0.70 | 183.93% | -17.36% |
The latest Lipella Pharmaceuticals stock forecast, released on Apr 09, 2024 by Jason McCarthy from Maxim Group, set a price target of $2.00, which represents a 183.93% increase from the stock price at the time of the forecast ($0.70), and a -17.36% decrease from LIPO last price ($2.42).
Lipella Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $2.42 | $2.42 | $2.42 |
| Upside/Downside | -100.00% | -100.00% | -17.36% |
In the current month, the average price target of Lipella Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lipella Pharmaceuticals's last price of $2.42. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Lipella Pharmaceuticals Financial Forecast
Lipella Pharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | $82.15M | $80.38M | $136.00K | $146.00K |
| High Forecast | $82.15M | $80.38M | $136.00K | $146.00K |
| Low Forecast | $82.15M | $80.38M | $136.00K | $146.00K |
| # Analysts | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - |
Lipella Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LIPO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Lipella Pharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - |
| Avg Forecast | $-33.77M | $-33.04M | $-55.91K | $-60.02K |
| High Forecast | $-33.77M | $-33.04M | $-55.91K | $-60.02K |
| Low Forecast | $-33.77M | $-33.04M | $-55.91K | $-60.02K |
| Surprise % | - | - | - | - |
undefined analysts predict LIPO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lipella Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Lipella Pharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - |
| Avg Forecast | $-12.53M | $-10.74M | $-10.74M | $-14.32M |
| High Forecast | $-12.53M | $-10.74M | $-10.74M | $-14.32M |
| Low Forecast | $-12.53M | $-10.74M | $-10.74M | $-14.32M |
| Surprise % | - | - | - | - |
Lipella Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LIPO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lipella Pharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - |
| Avg Forecast | $146.78M | $143.62M | $243.00K | $260.87K |
| High Forecast | $146.78M | $143.62M | $243.00K | $260.87K |
| Low Forecast | $146.78M | $143.62M | $243.00K | $260.87K |
| Surprise % | - | - | - | - |
Lipella Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LIPO last annual SG&A of $NaN (undefined).
Lipella Pharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - |
| Avg Forecast | $-1.12 | $-0.96 | $-0.96 | $-1.28 |
| High Forecast | $-1.12 | $-0.96 | $-0.96 | $-1.28 |
| Low Forecast | $-1.12 | $-0.96 | $-0.96 | $-1.28 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Lipella Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LIPO previous annual EPS of $NaN (undefined).
Lipella Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals | $1.50 | $6.00 | 300.00% | Buy |
| ACRV | Acrivon Therapeutics | $6.44 | $21.83 | 238.98% | Buy |
| FENC | Fennec Pharmaceuticals | $4.72 | $15.75 | 233.69% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| CELC | Celcuity | $12.73 | $31.50 | 147.45% | Buy |
| ELVN | Enliven Therapeutics | $25.41 | $39.50 | 55.45% | Buy |
| MNPR | Monopar Therapeutics | $19.71 | $29.50 | 49.67% | Buy |
| LIPO | Lipella Pharmaceuticals | $2.42 | $2.00 | -17.36% | - |